- Price
- $69.10
- Day
- +1.45%
- Mkt Cap
- $5.77B
- 52W Range
- $43.18 – $90.87
- Volume
- 1.37M
- Beta
- 0.53
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read full article
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article
PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
Read full article
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 – WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026.
Read full article
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago.
Read full article
Fifth Third Bancorp increased its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 12,362.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,447 shares of the biopharmaceutical company's stock after acquiring an additional 17,307 shares
Read full article
CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026.
Read full article
Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,814.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,813 shares of the biopharmaceutical company's stock after buying an additional 52,572 shares during the quarter. Bessemer
Read full article
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2026, at 4:30 p.m.
Read full article